Report Code: CMI35937

Published Date: December 2023

Pages: 320+

Category: Pharmaceuticals

Report Snapshot

CAGR: 8.1%

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Pfizer Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Nifedipine Market is expected to record a CAGR of 8.1% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 824.3 Million. By 2032, the valuation is anticipated to reach USD 1,661.5 Million.

Nifedipine Specification

Property Specification
Chemical name 1,4-dimethyl 2,6-dimethyl-3,5-dicarbomethoxy-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester
Molecular formula C17H18N2O6
Molecular weight 346.35 g/mol
CAS number 326-47-7
Appearance White or almost white, crystalline powder
Melting point 174-177°C
Solubility Practically insoluble in water, soluble in ethanol, slightly soluble in ether
Assay Not less than 99.0% and not more than 101.0% of C17H18N2O6, calculated on the anhydrous basis
Related substances Not more than 1.0% of total impurities, determined by thin-layer chromatography
Loss on drying Not more than 0.5%, determined at 105°C for 4 hours
Residue on ignition Not more than 0.1%
Heavy metals Not more than 0.002%
Organic solvents Not more than 0.2%, determined by gas chromatography
Source: According to CMI Market Research Team Analysis

The Nifedipine market encompasses pharmaceuticals, notably calcium channel blockers, used to treat hypertension and angina. Shaped by factors such as cardiovascular disease prevalence, generic competition, and technological advancements, the market has witnessed shifts. The COVID-19 impact emphasized telehealth adoption and chronic disease management.

Key players like Pfizer and Novartis drive market growth through R&D for innovative formulations. With a focus on patient adherence and global economic factors, the market adapts to changing healthcare norms. Ongoing initiatives by industry leaders continue to shape the Nifedipine market in response to evolving healthcare needs.

Nifedipine Market – Significant Growth Factors

The Nifedipine Market presents significant growth opportunities due to several factors:

  • Increasing Prevalence of Cardiovascular Diseases: The rising global incidence of cardiovascular diseases, including hypertension and angina, acts as a primary driver for the Nifedipine market, creating a sustained demand for medications to manage these conditions.
  • Technological Advancements in Drug Formulations: Ongoing research and development efforts have led to technological advancements, resulting in improved formulations of Nifedipine. Enhanced drug delivery systems and innovative formulations contribute to increased efficacy and patient compliance.
  • Growing Aging Population: The demographic shift towards an aging population is a significant driver. As the elderly are more prone to cardiovascular issues, the demand for medications like Nifedipine is expected to rise in tandem with the aging demographic.
  • Expansion of Healthcare Infrastructure in Emerging Markets: The growth and improvement of healthcare infrastructure in emerging markets contribute to increased access to medications. As these regions focus on better healthcare services, the demand for cardiovascular drugs, including Nifedipine, experiences a positive impact.
  • Telehealth and Digital Health Integration: The increasing acceptance of telehealth services presents an opportunity for the Nifedipine market. Integrating digital health solutions for remote patient monitoring and consultations enhances accessibility, especially in regions with limited healthcare infrastructure.
  • Focus on Personalized Medicine: The trend towards personalized medicine opens opportunities for tailored treatments based on individual patient characteristics. Personalized approaches in prescribing Nifedipine can lead to better outcomes and patient satisfaction.
  • Expansion into Untapped Markets: There is an opportunity for market expansion by entering untapped geographic regions or demographic segments. Strategic initiatives to reach underserved populations can result in increased market penetration and growth for Nifedipine.

Nifedipine Market – Mergers and Acquisitions

The Nifedipine Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Nifedipine Market include:

  • In 2022, Alembic Pharmaceuticals Limited obtained final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) of Nifedipine Extended-release Tablets USP in 30mg, 60mg, and 90mg strengths, reinforcing its position in the generic medicine market.
  • In 2020, AVET launched nifedipine soft gel capsules, available in 10mg and 20mg potency. This AB-rated generic equivalent to Procardia® enhances Avet’s portfolio of generic oral solid products. The spokesperson anticipates the drug’s entry will enable competitive positioning in the hypertension-dominated market.

These mergers and presence helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Nifedipine Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.


Nifedipine Market Vyndaqel Market Naloxone Market
CAGR 8.1% (Approx) CAGR 15.8% (Approx) CAGR 11% (Approx)
USD 1661.5 Million by 2032 USD 9.2 Billion by 2032 USD 2,470.2 Million by 2032

Nifedipine Market – Significant Threats

The Nifedipine Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Generic Competition: The presence of generic alternatives poses a significant threat to the Nifedipine market. Generic versions often lead to price erosion, reducing profit margins for branded medications and impacting market share.
  • Emergence of Alternative Therapies: The development and adoption of alternative therapies for cardiovascular diseases may divert market share from Nifedipine. Advances in medical research and the introduction of novel treatment options could pose a threat to the drug’s market dominance.
  • Stringent Regulatory Challenges: Evolving regulatory standards and challenges in obtaining approvals for new formulations or indications can hinder market growth. Compliance with stringent regulatory requirements may lead to delays and increased costs in product development.
  • Healthcare Policy Changes: Changes in healthcare policies and reimbursement structures can impact the affordability and accessibility of Nifedipine. Alterations in government healthcare programs or insurance coverage may affect patient access to medication.
  • Adverse Effects and Safety Concerns: Reports of adverse effects or safety concerns associated with Nifedipine can significantly impact its market performance. Concerns related to side effects may lead to decreased prescribing rates and a decline in patient confidence, affecting overall market demand.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 824.3 Million
Projected Market Size in 2032 USD 1,661.5 Million
Market Size in 2022 USD 762.5 Million
CAGR Growth Rate 8.1% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Product Type, Application, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Product Type

  • Nifedipine Controlled-Release Tablets: Nifedipine controlled-release tablets are designed for gradual and sustained release of the medication, providing consistent blood pressure control. Market trends indicate a growing preference for controlled-release formulations due to improved patient adherence, reduced side effects, and the convenience of less frequent dosing.
  • Nifedipine Extended-Action Tablets: Nifedipine extended-action tablets deliver the drug over an extended period, offering prolonged therapeutic effects. Market trends highlight a demand for extended-action formulations, driven by the emphasis on once-daily dosing, enhanced treatment adherence, and improved patient convenience in managing cardiovascular conditions.

By Application

  • Primary Pulmonary Hypertension: Nifedipine is used to manage primary pulmonary hypertension by relaxing blood vessels in the lungs, and reducing strain on the heart. Increasing awareness and diagnosis of primary pulmonary hypertension drive demand for Nifedipine, supported by ongoing advancements in pulmonary hypertension treatment.
  • Heart Failure: Nifedipine aids in heart failure treatment by improving blood flow and reducing the heart’s workload. The growing incidence of heart failure fuels demand for Nifedipine, with ongoing research focusing on combination therapies for enhanced efficacy.
  • Raynaud’s Syndrome: Nifedipine is prescribed for Raynaud’s syndrome, alleviating vasospasm in blood vessels. The increasing prevalence of Raynaud’s syndrome propels Nifedipine market growth, driven by the drug’s vasodilatory effects and its role in symptom management.
  • Cephalalgia: Nifedipine is utilized for treating cephalalgia, and addressing vascular headaches. Growing recognition of Nifedipine’s efficacy in managing vascular headaches contributes to its continued use, supported by advancements in headache treatment.
  • Bronchial Asthma: Nifedipine’s bronchodilator effects find application in bronchial asthma management. Nifedipine’s role in bronchial asthma has gained attention, with research exploring its potential in combination therapies and personalized treatment approaches.
  • Premature Labor: Nifedipine is employed to delay premature labor by relaxing uterine muscles. Increasing emphasis on maternal and fetal health drives demand for Nifedipine in managing premature labor, with ongoing research focusing on safety and efficacy.

Global Nifedipine Market 2023–2032 (By Million)

By Distribution Channel

  • Hospital Pharmacies: Hospital pharmacies are facilities within medical institutions that dispense medications. In the Nifedipine market, hospital pharmacies play a crucial role in providing immediate access to the drug for inpatients. Trends include streamlined procurement processes, inventory management systems, and an emphasis on formulary optimization for cardiovascular medications.
  • Retail Pharmacies: Retail pharmacies, commonly found in community settings, offer Nifedipine to outpatients. Trends involve increased patient education at the pharmacy level, personalized consultations, and a growing focus on cardiovascular health awareness campaigns to drive demand for Nifedipine.
  • Online Pharmacies: Online pharmacies operate through digital platforms, providing a convenient channel for purchasing Nifedipine. Trends include the growing popularity of e-commerce in healthcare, increased adoption of telemedicine, and stringent measures to ensure the authenticity and safety of medications purchased online.
  • Others: The “Others” category includes specialty pharmacies, independent pharmacies, and non-traditional distribution channels. Trends within this segment could involve strategic partnerships between pharmaceutical companies and unconventional distribution channels, such as clinics or healthcare providers, to enhance Nifedipine accessibility and reach diverse patient populations.

Global Nifedipine Market 2023–2032 (By Distribution Channel)

Nifedipine Market – Regional Analysis

The Nifedipine Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, the Nifedipine market is influenced by a trend towards personalized medicine. Advanced healthcare infrastructure supports precision medicine approaches, leading to tailored prescriptions. Additionally, the region sees a rise in digital health integration, with telehealth services and online platforms enhancing patient access to Nifedipine.
  • Europe: Europe showcases a trend of increasing emphasis on preventive healthcare. Government initiatives and public health campaigns promote cardiovascular health awareness, driving demand for medications like Nifedipine. The market also experiences notable growth in research collaborations, fostering advancements in drug formulations and treatment protocols.
  • Asia-Pacific: The Asia-Pacific region witnesses a significant trend of expanding healthcare access in rural areas. Governments invest in healthcare infrastructure development, facilitating increased availability of Nifedipine. Telemedicine adoption is also rising, improving patient reach. Moreover, there is a surge in collaborative efforts between pharmaceutical companies and local healthcare providers.
  • LAMEA (Latin America, Middle East, and Africa): In LAMEA, a notable trend involves a shift towards value-based care models. Governments and healthcare providers are focusing on achieving better health outcomes, promoting efficient use of resources, and enhancing patient satisfaction. This trend influences the adoption of medications like Nifedipine as part of comprehensive cardiovascular care strategies.

Global Nifedipine Market 2023–2032 (By Product Type)

Competitive Landscape – Nifedipine Market

The Nifedipine Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Pfizer Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy’s Laboratories Ltd.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the Nifedipine market often adopt innovation and development strategies to establish a foothold. Companies leveraging advanced drug formulations, incorporating digital health solutions, and emphasizing patient-centric approaches gain traction.

Key players dominating the market, such as Pfizer, Novartis, and Johnson & Johnson, maintain their positions through extensive research, established brand recognition, and strategic collaborations. These leaders drive market growth by continually advancing formulations, ensuring regulatory compliance, and participating in initiatives that enhance overall cardiovascular health awareness, solidifying their market dominance.

The Nifedipine Market is segmented as follows:

By Product Type

  • Nifedipine Controlled-Release Tablets
  • Nifedipine Extended Action Tablets

By Application

  • Primary Pulmonary Hypertension
  • Heart Failure
  • Raynaud’s Syndrome
  • Cephalalgia
  • Bronchial Asthma
  • Premature Labor

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Nifedipine Market, (2024 – 2033) (USD Million)
    • 2.2 Global Nifedipine Market: snapshot
  • Chapter 3. Global Nifedipine Market – Industry Analysis
    • 3.1 Nifedipine Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Prevalence of Cardiovascular Diseases
      • 3.2.2 Technological Advancements in Drug Formulations
      • 3.2.3 Growing Aging Population
      • 3.2.4 Expansion of Healthcare Infrastructure in Emerging Markets
      • 3.2.5 Telehealth and Digital Health Integration
      • 3.2.6 Focus on Personalized Medicine
      • 3.2.7 Expansion into Untapped Markets.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Product Type
      • 3.7.2 Market Attractiveness Analysis By Application
      • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • Chapter 4. Global Nifedipine Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Nifedipine Market: Company Market Share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, collaboration, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Nifedipine Market – Product Type Analysis
    • 5.1 Global Nifedipine Market Overview: By Product Type
      • 5.1.1 Global Nifedipine Market Share, By Product Type, 2022 and – 2033
    • 5.2 Nifedipine Controlled-Release Tablets
      • 5.2.1 Global Nifedipine Market by Nifedipine Controlled-Release Tablets, 2024 – 2033 (USD Million)
    • 5.3 Nifedipine Extended Action Tablets
      • 5.3.1 Global Nifedipine Market by Nifedipine Extended Action Tablets, 2024 – 2033 (USD Million)
  • Chapter 6. Global Nifedipine Market – Application Analysis
    • 6.1 Global Nifedipine Market Overview: By Application
      • 6.1.1 Global Nifedipine Market Share, By Application, 2022 and – 2033
    • 6.2 Primary Pulmonary Hypertension
      • 6.2.1 Global Nifedipine Market by Primary Pulmonary Hypertension, 2024 – 2033 (USD Million)
    • 6.3 Heart Failure
      • 6.3.1 Global Nifedipine Market by Heart Failure, 2024 – 2033 (USD Million)
    • 6.4 Raynaud’s Syndrome
      • 6.4.1 Global Nifedipine Market by Raynaud’s Syndrome, 2024 – 2033 (USD Million)
    • 6.5 Cephalalgia
      • 6.5.1 Global Nifedipine Market by Cephalalgia, 2024 – 2033 (USD Million)
    • 6.6 Bronchial Asthma
      • 6.6.1 Global Nifedipine Market by Bronchial Asthma, 2024 – 2033 (USD Million)
    • 6.7 Premature Labor
      • 6.7.1 Global Nifedipine Market by Premature Labor, 2024 – 2033 (USD Million)
  • Chapter 7. Global Nifedipine Market – Distribution Channel Analysis
    • 7.1 Global Nifedipine Market Overview: By Distribution Channel
      • 7.1.1 Global Nifedipine Market Share, By Distribution Channel, 2022 and – 2033
    • 7.2 Hospital Pharmacies
      • 7.2.1 Global Nifedipine Market by Hospital Pharmacies, 2024 – 2033 (USD Million)
    • 7.3 Retail Pharmacies
      • 7.3.1 Global Nifedipine Market by Retail Pharmacies, 2024 – 2033 (USD Million)
    • 7.4 Online Pharmacies
      • 7.4.1 Global Nifedipine Market by Online Pharmacies, 2024 – 2033 (USD Million)
    • 7.5 Others
      • 7.5.1 Global Nifedipine Market by Others, 2024 – 2033 (USD Million)
  • Chapter 8. Nifedipine Market – Regional Analysis
    • 8.1 Global Nifedipine Market Regional Overview
    • 8.2 Global Nifedipine Market Share, by Region, 2022 & – 2033 (USD Million)
    • 8.3. North America
      • 8.3.1 North America Nifedipine Market, 2024 – 2033 (USD Million)
        • North America Nifedipine Market, by Country, 2024 – 2033 (USD Million)
    • 8.4 North America Nifedipine Market, by Product Type, 2024 – 2033
      • 8.4.1 North America Nifedipine Market, by Product Type, 2024 – 2033 (USD Million)
    • 8.5 North America Nifedipine Market, by Application, 2024 – 2033
      • 8.5.1 North America Nifedipine Market, by Application, 2024 – 2033 (USD Million)
    • 8.6 North America Nifedipine Market, by Distribution Channel, 2024 – 2033
      • 8.6.1 North America Nifedipine Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 8.7. Europe
      • 8.7.1 Europe Nifedipine Market, 2024 – 2033 (USD Million)
        • Europe Nifedipine Market, by Country, 2024 – 2033 (USD Million)
    • 8.8 Europe Nifedipine Market, by Product Type, 2024 – 2033
      • 8.8.1 Europe Nifedipine Market, by Product Type, 2024 – 2033 (USD Million)
    • 8.9 Europe Nifedipine Market, by Application, 2024 – 2033
      • 8.9.1 Europe Nifedipine Market, by Application, 2024 – 2033 (USD Million)
    • 8.10 Europe Nifedipine Market, by Distribution Channel, 2024 – 2033
      • 8.10.1 Europe Nifedipine Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 8.11. Asia Pacific
      • 8.11.1 Asia Pacific Nifedipine Market, 2024 – 2033 (USD Million)
        • Asia Pacific Nifedipine Market, by Country, 2024 – 2033 (USD Million)
    • 8.12 Asia Pacific Nifedipine Market, by Product Type, 2024 – 2033
      • 8.12.1 Asia Pacific Nifedipine Market, by Product Type, 2024 – 2033 (USD Million)
    • 8.13 Asia Pacific Nifedipine Market, by Application, 2024 – 2033
      • 8.13.1 Asia Pacific Nifedipine Market, by Application, 2024 – 2033 (USD Million)
    • 8.14 Asia Pacific Nifedipine Market, by Distribution Channel, 2024 – 2033
      • 8.14.1 Asia Pacific Nifedipine Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 8.15. Latin America
      • 8.15.1 Latin America Nifedipine Market, 2024 – 2033 (USD Million)
        • Latin America Nifedipine Market, by Country, 2024 – 2033 (USD Million)
    • 8.16 Latin America Nifedipine Market, by Product Type, 2024 – 2033
      • 8.16.1 Latin America Nifedipine Market, by Product Type, 2024 – 2033 (USD Million)
    • 8.17 Latin America Nifedipine Market, by Application, 2024 – 2033
      • 8.17.1 Latin America Nifedipine Market, by Application, 2024 – 2033 (USD Million)
    • 8.18 Latin America Nifedipine Market, by Distribution Channel, 2024 – 2033
      • 8.18.1 Latin America Nifedipine Market, by Distribution Channel, 2024 – 2033 (USD Million)
    • 8.19. The Middle East and Africa
      • 8.19.1 The Middle-East and Africa Nifedipine Market, 2024 – 2033 (USD Million)
        • The Middle-East and Africa Nifedipine Market, by Country, 2024 – 2033 (USD Million)
    • 8.20 The Middle-East and Africa Nifedipine Market, by Product Type, 2024 – 2033
      • 8.20.1 The Middle-East and Africa Nifedipine Market, by Product Type, 2024 – 2033 (USD Million)
    • 8.21 The Middle-East and Africa Nifedipine Market, by Application, 2024 – 2033
      • 8.21.1 The Middle-East and Africa Nifedipine Market, by Application, 2024 – 2033 (USD Million)
    • 8.22 The Middle-East and Africa Nifedipine Market, by Distribution Channel, 2024 – 2033
      • 8.22.1 The Middle-East and Africa Nifedipine Market, by Distribution Channel, 2024 – 2033 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1 Pfizer Inc.
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 Novartis International AG
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 AstraZeneca PLC
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Bayer AG
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Johnson & Johnson
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 Teva Pharmaceutical Industries Ltd.
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 Mylan N.V.
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Sanofi S.A.
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 GlaxoSmithKline plc
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Merck & Co. Inc.
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Boehringer Ingelheim International GmbH
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
    • 9.12 Sun Pharmaceutical Industries Ltd.
      • 9.12.1 Overview
      • 9.12.2 Financials
      • 9.12.3 Product Portfolio
      • 9.12.4 Business Strategy
      • 9.12.5 Recent Developments
    • 9.13 Lupin Limited
      • 9.13.1 Overview
      • 9.13.2 Financials
      • 9.13.3 Product Portfolio
      • 9.13.4 Business Strategy
      • 9.13.5 Recent Developments
    • 9.14 Torrent Pharmaceuticals Ltd.
      • 9.14.1 Overview
      • 9.14.2 Financials
      • 9.14.3 Product Portfolio
      • 9.14.4 Business Strategy
      • 9.14.5 Recent Developments
    • 9.15 Dr. Reddy’s Laboratories Ltd.
      • 9.15.1 Overview
      • 9.15.2 Financials
      • 9.15.3 Product Portfolio
      • 9.15.4 Business Strategy
      • 9.15.5 Recent Developments
    • 9.16 Others.
      • 9.16.1 Overview
      • 9.16.2 Financials
      • 9.16.3 Product Portfolio
      • 9.16.4 Business Strategy
      • 9.16.5 Recent Developments
List Of Figures

Figures No 1 to 28

List Of Tables

Tables No 1 to 77

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers

Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Pfizer Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Reddy’s Laboratories Ltd.
  • Others


The key factors driving the Market are Increasing Prevalence of Cardiovascular Diseases, Technological Advancements in Drug Formulations, Growing Aging Population, Expansion of Healthcare Infrastructure in Emerging Markets, Telehealth and Digital Health Integration, Focus on Personalized Medicine And Expansion into Untapped Markets.

The “Nifedipine Controlled-Release Tablets” category dominated the market in 2022.

The key players in the market are Pfizer Inc., Novartis International AG, AstraZeneca PLC, Bayer AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Others.

“Europe” had the largest share in the Nifedipine Market.

The global market is projected to grow at a CAGR of 8.1% during the forecast period, 2023-2032.

The Nifedipine Market size was valued at USD 824.3 Million in 2023.












What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?